Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Best Practices for Treatment Team Collaboration in the Use of Radiopharmaceutical Therapy in the United States.

JCO oncology practice·2026
Same author

Twist1 overexpression models an aggressive subtype of pancreatic ductal adenocarcinoma in vivo.

Lab animal·2026
Same author

Response to the FDA Dosage Optimization Draft Guidance for Radiopharmaceutical Therapies.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration.

The Lancet. Oncology·2026
Same author

Integrating systemic therapy and metastasis-directed therapy in oligometastatic hormone-sensitive prostate cancer.

Prostate cancer and prostatic diseases·2025
Same author

Reply to: Revisiting Radium-223 in Oligometastatic Castration-Sensitive Prostate Cancer: RAVENS Trial Insights.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

Related Experiment Video

Updated: Jul 17, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K

PSMA-targeted therapy for non-prostate cancers.

Jarey H Wang1, Ana P Kiess1

  • 1Department of Radiation Oncology and Molecular Radiation Sciences, School of Medicine, Johns Hopkins University, Baltimore, MD, United States.

Frontiers in Oncology
|August 30, 2023
PubMed
Summary

Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) shows promise beyond prostate cancer. Research is exploring its use in salivary gland cancers, renal cell carcinoma, glioma, and sarcoma, with further studies needed for optimal application.

Keywords:
PSMAglioblastomalutetium-177non-prostate cancersradioligand therapy (RLT)renal cell carcinomasalivary gland cancersoft tissue sarcoma

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.4K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K

Related Experiment Videos

Last Updated: Jul 17, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.4K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiopharmaceutical Therapy

Background:

  • Radioligand therapy (RLT) is vital for aggressive cancers like metastatic castrate-resistant prostate cancer (m-CRPC).
  • Prostate-specific membrane antigen (PSMA)-targeted RLT is now FDA-approved for m-CRPC.
  • PSMA expression in non-prostate tumors suggests potential therapeutic applications.

Purpose of the Study:

  • To review the current clinical progress of PSMA-targeted RLT in non-prostate cancers.
  • To highlight early findings and potential benefits in various malignancies.
  • To identify areas for future research in PSMA RLT for new indications.

Main Methods:

  • Literature review of clinical studies and case series involving PSMA RLT in non-prostate cancers.
  • Analysis of reported efficacy, safety, and patient selection criteria.
  • Identification of key research questions for advancing PSMA RLT in new cancer types.

Main Results:

  • Early data from small cohorts suggest promise for PSMA RLT in salivary gland cancers, renal cell carcinoma, high-grade glioma, and soft tissue sarcoma.
  • PSMA expression in tumor parenchyma and neovasculature is a key factor for targeting.
  • Patient selection and understanding PSMA expression levels are critical for treatment success.

Conclusions:

  • PSMA-targeted RLT is a promising therapeutic strategy for select non-prostate cancers.
  • Further research is essential to optimize dosimetry, utilize PSMA PET/CT imaging as a biomarker, and establish safety and efficacy profiles.
  • Identifying specific patient populations who will benefit most from PSMA RLT is crucial for clinical implementation.